Durect announces 1-for-10 reverse stock split

Cupertino, calif. , nov. 28, 2022 /prnewswire/ -- durect corporation (nasdaq: drrx), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that durect's board of directors today determined that the company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m.
DRRX Ratings Summary
DRRX Quant Ranking